Search Results
30 items found for "Yohan Han"
- 📰 GPCR Weekly News, July 1 to 7, 2024
Jianming Han , Tao Che for their analysis of GPCR-G protein selectivity revealed by structural pharmacology
- Structural landscape of the Chemokine Receptor system
antagonist ([5P7]CCL5), and a small-molecule inverse agonist (maraviroc) (Tan, Zhu et al. 2013, Zheng, Han its constitutive activity (Yen, Schafer et al. 2022) which is also supported by mutagenesis studies (Han
- Profiling Immune Cell and Platelet Transcriptomes
A study published in Scientific Data by Arne Hansen et a l has introduced a sensitive method for detecting
- 📰 GPCR Weekly Buzz: Exciting Schedule Shifts for Principles of Pharmacology I & II | August 12-18, 2024
diastereomers activate an endogenous receptor and suppress heart rate in the Pacific abalone Haliotis discus hannai
- 📰 GPCR Weekly News, June 3 to June 9, 2024
Aylin Hanyaloglu, Caroline Gorvin, and Alejandra Tomas.
- Navigating the Signaling Network: RTK and GPCR Crosstalk Uncovered
On the other hand, RTKs play pivotal roles in growth factor signaling, regulating cell growth, differentiation
- 📰 GPCR Weekly News, May 13 to 19, 2024
Illuminating GPCR Research: FRET and BRET-Based Sensors Shed Light on Cellular Signaling Abigail Walker, Aylin Hanyaloglu
- 📰 GPCR Weekly News, April 29 to May 5, 2024
Today is also the first session of our hands-on workshop with Dr. Sam Hoare.
- 📰 GPCR Weekly News, April 22 to 28, 2024
GPCR University hands-on workshop with Dr.
- 📰 GPCR Weekly News, April 15 to 21, 2024
GPCR University hands-on workshop with Dr. Sam Hoare about this hands-on workshop HERE ⬇⬇⬇ Dr. as Chief Executive Officer Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok
- 📰 GPCR Weekly News, April 8 to 14, 2024
GPCR University hands-on workshop with Dr. Sam Hoare about this hands-on workshop HERE ⬇⬇⬇ Dr.
- From DNA day to GPCR genomics
Molecular pharmacology, 63(6), 1256–1272. https://doi.org/10.1124/mol.63.6.1256 Syed Haneef, S.
- 📰 GPCR Weekly News, April 1 to 7, 2024
GPCR University hands-on workshop with Dr.
- 📰 GPCR Weekly News, March 25 to March 31, 2024
GPCR University hands-on workshop with Dr.
- GPCRs are not simple on-off switches: deep dive into GPCR-ligand interactions
On the other hand, selectivity could be achieved by merging both orthosteric and allosteric pharmacophores
- 📰 GPCR Weekly News, February 5 to 11, 2024
Magdalena M Scharf, Antonella Di Pizio, Ines Liebscher, Hannes Schihada, and Gunnar Schulte et al. on
- Chemokine receptor-targeted drug discovery: progress and challenges
On the other hand, Shall and Proudfoot excluded the idea of molecular redundancy, pointing out that,
- 📰 GPCR Weekly News, October 30 to November 4, 2023
Hannes Schihada and his lab team developed fluorescent analogues for real-time binding studies of orphan
- Targeting Intracellular Allosteric Sites in GPCRs
On the other hand, selectivity could be achieved by merging both orthosteric and allosteric pharmacophores On the other hand, positive allosteric modulators that target intracellular allosteric sites can enhance
- Decoding β-Arrestins: from Structure to function
Cryo-EM, on the other hand, requires less protein and has evolved to achieve resolutions comparable to
- 📰 GPCR Weekly News, July 31 to August 6, 2023
Loan Facility with Hercules Capital Gene-to-structure and Europe give Proteros customers a winning hand
- Artificial intelligence – faster, smarter, cheaper GPCR drug discovery
typically use traditional ML models, such as decision trees and support vector machines which require handcrafted becoming infeasible for a human to interpret, in contrast with alternative ML models which comprise handcrafted unsupervised machine learning: most applications of ML in GPCR drug discovery have relied on traditional, hand-crafted
- Feeder or trigger – CCR2 as a scavenger and regulator of cell migration
Hansell et al. 2011); and it may interfere with other chemokine receptors which share the ligands and
- Unlocking the Therapeutic Potential of Previously Undruggable GPCRs
However, the receptors that these medicines target have been described as the ‘low-hanging’ fruit, and
- Transmembrane domains of GPCR dimers – a novel hot spot for drug discovery
(TMD), with the most compelling studies revealing that the transmembrane helices TM4 and TM5 on one hand , and TM1 and TM7 on the other hand, form possible dimerization interfaces (Ploier, B. et al. 2016; Dijkman
- β-arrestin1 and 2 exhibit distinct phosphorylation-dependent conformations when coupling to the...
associate with the active parathyroid hormone 1 receptor (PTH1R) in different complex configurations ("hanging
- Gαs and Gαq/11 protein coupling bias of two AVPR2 mutants (R68W and V162A) that cause nephrogenic di
On the other hand, they showed the ability to couple with Gαq/11 protein and make Ca2+ mobilization at
- Drug Discovery Picks Up the Pace, Stays on Target
January 2022 "Voltaire argued, “Perfection is attained by slow degrees; it requires the hand of time